Interesting use of technology from the AAN Meeting
Posted: Wed Apr 05, 2006 8:51 am
This abstract talks about using chip arrays to look at CSF. It seems that technology like this should enable a more thorough analysis of what's really going on at a protein-level...I think...
[P06.169] Identification of CSF Proteome Modifications in Multiple Sclerosis Using a Protein Chip Array Technology
Arnaud Lacour, Lille, Nord, France, Didier Lefranc, Jerome De Seze, Brigitte Onraed, Sylvain Dubucquoi, Gilbert Briand, Lionel Prin, Patrick Vermersch, Lille, France
OBJECTIVE: The aim of this study was to investigate changes occuring in CSF proteome in relapsing-remitting MS by a protein chip array approach in large groups of patients.
BACKGROUND: Detection of IgG oligoclonal bands within the cerebrospinal fluid (CSF) is the most sensitive and specific biological hallmark of multiple sclerosis (MS). Nevertheless, few proteomic studies have described additionnal proteome modifications in MS CSF, but using two-dimensionnal electrophoresis, in small groups of patients and with contradictory results.
DESIGN/METHODS: CSF samples from 92 RR-MS and 121 non-inflammatory neurological diseases (controls) patients stored in an home-made database were analysed by a protein chip array technology (surface enhanced laser desorption/ionization-time of flight-mass spectroscopy, SELDI-TOF-MS).
RESULTS: We first tested various profiling conditions to determine the most appropriate protocol: crude CSF, CM10 protein chip (cationic exchanger surface) with pH 4 binding and washing buffers. This protocol allowed the detection of approximately 30 m/Z peaks in MS and control CSF samples. Moreover, we found statistically significant differences (p < 0.05) regarding five overexpressed m/Z peaks in RR-MS samples compared to control samples. Two differentially expressed m/Z peaks (11.9 and 12.1 kDa) have been purified and the identification of the related proteins is in progress. Preliminary results show that these two peaks are not detected in serum, either in MS or control samples.
CONCLUSIONS/RELEVANCE: The SELDI-TOF technology is a relevant tool for CSF protein profiling, allowing identification of five overexpressed m/Z peaks in our RR-MS CSF samples compared to non-inflammatory neurological diseases CSF samples. Proteomic analysis of serum samples of RR-MS and control patients and of CSF samples from other clinical forms of MS and inflammatory neurological diseases patients are the next stages of our study.
Thursday, April 6, 2006 3:00 PM
[P06.169] Identification of CSF Proteome Modifications in Multiple Sclerosis Using a Protein Chip Array Technology
Arnaud Lacour, Lille, Nord, France, Didier Lefranc, Jerome De Seze, Brigitte Onraed, Sylvain Dubucquoi, Gilbert Briand, Lionel Prin, Patrick Vermersch, Lille, France
OBJECTIVE: The aim of this study was to investigate changes occuring in CSF proteome in relapsing-remitting MS by a protein chip array approach in large groups of patients.
BACKGROUND: Detection of IgG oligoclonal bands within the cerebrospinal fluid (CSF) is the most sensitive and specific biological hallmark of multiple sclerosis (MS). Nevertheless, few proteomic studies have described additionnal proteome modifications in MS CSF, but using two-dimensionnal electrophoresis, in small groups of patients and with contradictory results.
DESIGN/METHODS: CSF samples from 92 RR-MS and 121 non-inflammatory neurological diseases (controls) patients stored in an home-made database were analysed by a protein chip array technology (surface enhanced laser desorption/ionization-time of flight-mass spectroscopy, SELDI-TOF-MS).
RESULTS: We first tested various profiling conditions to determine the most appropriate protocol: crude CSF, CM10 protein chip (cationic exchanger surface) with pH 4 binding and washing buffers. This protocol allowed the detection of approximately 30 m/Z peaks in MS and control CSF samples. Moreover, we found statistically significant differences (p < 0.05) regarding five overexpressed m/Z peaks in RR-MS samples compared to control samples. Two differentially expressed m/Z peaks (11.9 and 12.1 kDa) have been purified and the identification of the related proteins is in progress. Preliminary results show that these two peaks are not detected in serum, either in MS or control samples.
CONCLUSIONS/RELEVANCE: The SELDI-TOF technology is a relevant tool for CSF protein profiling, allowing identification of five overexpressed m/Z peaks in our RR-MS CSF samples compared to non-inflammatory neurological diseases CSF samples. Proteomic analysis of serum samples of RR-MS and control patients and of CSF samples from other clinical forms of MS and inflammatory neurological diseases patients are the next stages of our study.
Thursday, April 6, 2006 3:00 PM